Which Types of Biomarkers Truly Benefit AD?
Johannes Streffer, Director, Experimental Medicine Europe, Janssen Research & Development, Janssen Pharmaceutica NV, speaks to Andrea Charles from Pharma IQ, about where he feels the focus really lies at the moment for experimental medicine in Alzheimer’s disease. Streffer also discusses how biomarkers are driving CNS therapies through the clinical phases and which types of biomarkers truly benefit the AD area.
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.